{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:25:01Z","timestamp":1783704301750,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"internal funds of KroHem, the Croatian Cooperative Group for Hematologic Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear whether this risk is affected by the choice of the antibody (rituximab vs. obinutuzumab). To elucidate the role of antineoplastic therapy on COVID-19 outcomes, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID-19 between October 2020 and April 2021. A total of 314 patients were identified, 75 untreated, 61 off treatment and 178 on treatment. The mortality rate in untreated and off-treatment patients was 15% and 16%; 9% and 10% had prolonged infection. In the on-treatment group, 3% were still prolonged positive at time of data collection, 62% recovered and 35% died; 42% had prolonged infection. Disease type, use of anti-CD20 monoclonal antibodies, prior autologous stem-cell transplantation (ASCT) and line of treatment did not significantly affect mortality. Mortality was higher in older patients (p = 0.0078) and those treated with purine analogues (p = 0.012). Prolonged COVID-19 was significantly more frequent in patients treated with anti-CD20 monoclonal antibodies (p = 0.012), especially obinutuzumab, and purine analogues (p = 0.012). Age, prior ASCT and treatment line did not significantly affect risk of prolonged infection. These data suggest that increased age and use of purine analogues are main risk factors for increased mortality of COVID-19 in patients with lymphoid malignancies. Obinutuzumab further increases the risk of prolonged disease, but not of death, in comparison to rituximab. Epidemiological considerations should be taken into account when choosing the appropriate antineoplastic therapy for patients with lymphoid malignancies.<\/jats:p>","DOI":"10.3390\/biomedicines12020331","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:41:59Z","timestamp":1706694119000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era\u2014A Study of KroHem, the Croatian Group for Hematologic Diseases"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-4277","authenticated-orcid":false,"given":"Igor","family":"Aurer","sequence":"first","affiliation":[{"name":"University Hospital Centre Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-285X","authenticated-orcid":false,"given":"Ozren","family":"Jak\u0161i\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"University Hospital Dubrava, Av. G. \u0160u\u0161ka 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"additional","affiliation":[{"name":"University Hospital Centre Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mr\u0111enovi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Osijek, J. Huttlera 4, 31000 Osijek, Croatia"},{"name":"Medical School, University of Osijek, J. Huttlera 4, 31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodanka","family":"Ostoji\u0107-Koloni\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"University Hospital Merkur, Zaj\u010deva 19, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Lozi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Centre Split, Spin\u010di\u0107eva 1, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[{"name":"General Hospital Dr. Josip Ben\u010devi\u0107, A. \u0160tampara 42, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Novakovi\u0107-Coha","sequence":"additional","affiliation":[{"name":"University Hospital Centre Sisters of Mercy, Vinogradska c. 29, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Berne\u0161","sequence":"additional","affiliation":[{"name":"General Hospital Pula, Santoriova ul. 24a, 52100 Pula, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Kre\u010dak","sequence":"additional","affiliation":[{"name":"General Hospital \u0160ibenik, S. Radi\u0107a 83, 22000 \u0160ibenik, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, Bra\u0107e Branchetta 20, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mori\u0107-Peri\u0107","sequence":"additional","affiliation":[{"name":"General Hospital Zadar, B. Peri\u010di\u0107a 5, 23000 Zadar, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Naran\u010di\u0107","sequence":"additional","affiliation":[{"name":"General Hospital Zadar, B. Peri\u010di\u0107a 5, 23000 Zadar, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko","family":"Mitrovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"University Hospital Dubrava, Av. G. \u0160u\u0161ka 6, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Valkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, Bra\u0107e Branchetta 20, 51000 Rijeka, Croatia"},{"name":"University Hospital Centre Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102513","DOI":"10.1016\/j.canep.2023.102513","article-title":"Lymphoid blood cancers, incidence and survival 2005\u20132023: A report from the UK\u2019s Haematological Malignancy Research Network","volume":"88","author":"Lamb","year":"2023","journal-title":"Cancer Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1571826","DOI":"10.1155\/2022\/1571826","article-title":"Comorbidities, associated diseases, and risk assessment in COVID-19\u2014A systematic review","volume":"2022","author":"Fitero","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s00277-021-04656-z","article-title":"Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue","volume":"100","author":"Arcani","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Lamure","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","article-title":"COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma","volume":"5","author":"Gaitzsch","year":"2021","journal-title":"HemaSphere"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence, clinical presentation, relapses and outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2021005691","article-title":"A prognostic model for patients with lymphoma and COVID-19: A multicentre cohort study","volume":"6","author":"Visco","year":"2022","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: An update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.17937","article-title":"Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: Disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy","volume":"196","author":"Booth","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_13","first-page":"536","article-title":"Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: A report from the Argentine Society of Hematology","volume":"81","author":"Basquiera","year":"2021","journal-title":"Medicina"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1097\/HS9.0000000000000538","article-title":"Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study","volume":"5","author":"Navarro","year":"2021","journal-title":"HemaSphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Polliack","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)","volume":"47","author":"Aurer","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Moser","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bjh.18315","article-title":"Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19","volume":"198","author":"Shafat","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Negru, P.A., Radu, A.F., Vesa, C.M., Behl, T., Abdel-Daim, M.M., Nechifor, A.C., Endres, L., Stoicescu, M., Pasca, B., and Tit, D.M. (2022). Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus remdesivir. Biomed. Pharmacother., 147.","DOI":"10.1016\/j.biopha.2022.112700"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109046","DOI":"10.1016\/j.intimp.2022.109046","article-title":"A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies","volume":"110","author":"Noori","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10238-021-00746-4","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","volume":"22","author":"Gavriatopoulou","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell\u2013directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Serti\u0107, Z., Lucijani\u0107, M., Ba\u0161i\u0107-Kinda, S., Serventi Seiwerth, R., Peri\u0161a, V., Serti\u0107, D., Coha, B., Pulani\u0107, D., Peri\u0107, Z., and Desnica, L. (2022). Non-myelofibrosis chronic myeloproliferative neoplasm patients show better seroconversion rates after SARS-CoV-2 vaccination compared to other hematologic diseases: A multicentric prospective study of KroHem. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112892"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.puhe.2021.07.030","article-title":"COVID-19 incidence, hospitalizations and mortality trends in Croatia and school closure","volume":"198","author":"Svajda","year":"2021","journal-title":"Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sobczak, M., and Pawliczak, R. (2022). COVID-19 mortality rate determinants in selected Eastern European countries. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14567-x"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: Results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.jtct.2021.07.005","article-title":"Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients","volume":"27","author":"Mushtaq","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0711","DOI":"10.1097\/HS9.0000000000000711","article-title":"Outcome of COVID-19 in patients with mantle cell lymphoma-report from the European MCL registry","volume":"6","author":"Tilch","year":"2022","journal-title":"HemaSphere"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/2\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:31Z","timestamp":1760104351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/12\/2\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["biomedicines12020331"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines12020331","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}